Patents Assigned to Pfizer
  • Crystalline anhydrous and monohydrate benzoate salts of (2'S,3S)-3-hydroxy-N-2-[N-methyl-N-4-(N-propylamino-carbonyl)phenyl]amino-2-phenyl-ethylpyrrolidine
    Publication number: 20040235936
    Abstract: A process for preparing an anhydrous benzoate salt in crystalline form having the formula I: 1
    Type: Application
    Filed: April 23, 2003
    Publication date: November 25, 2004
    Applicant: Pfizer Inc.
    Inventors: George Quallich, Michael J. Castaldi
  • Pharmaceutical compositions of varenicline
    Publication number: 20040235850
    Abstract: The invention relates to novel pharmaceutical dosage forms of varenicline, which are useful for aiding smoking cessation and which have good storage stability. In particular, the present invention relates to formulations of varenicline wherein the dosage forms that are produced therefrom generate under specified storage conditions less than about 4% on a weight basis of the N-formyl and N-methyl degradation products.
    Type: Application
    Filed: May 18, 2004
    Publication date: November 25, 2004
    Applicant: Pfizer Inc
    Inventor: Kenneth C. Waterman
  • Method of treating certain cancers using an estrogen agonist/antagonist
    Patent number: 6821989
    Abstract: The present invention provides methods of treating cancer of the liver, ovarian cancer, a desmoid tumor, glioma, pancreatic cancer, or renal cell carcinoma using an estrogen agonist/antagonist. The present invention also provides kits that contain an estrogen agonist/antagonist for treating cancer of the liver, ovarian cancer, a desmoid tumor, glioma, pancreatic cancer, or renal cell carcinoma.
    Type: Grant
    Filed: January 23, 2002
    Date of Patent: November 23, 2004
    Assignee: Pfizer Inc.
    Inventor: Robert L. Rosati
  • Modulators of chemokine receptor activity
    Patent number: 6821964
    Abstract: Chemokine receptor antagonists, in particular, bicyclic diamine compounds of Formula (I) that act as antagonists of chemokine CCR2 and CCR3 receptors including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leucocyte accumulation are described herein.
    Type: Grant
    Filed: March 6, 2002
    Date of Patent: November 23, 2004
    Assignee: Pfizer Inc
    Inventors: Roberto Colon-Cruz, Mary T. Didiuk, Erin M. Duffy, Ravi Garigipati, Wan F. Lau, Wayne S. McDonald
  • Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
    Patent number: 6821985
    Abstract: This invention relates to methods of treating traumatic brain injury (TBI) or hypoxic or ischemic stroke, comprising administering to a patient in need of such treatment an NR2B subtype selective N-methyl-D-aspartate (NMDA) receptor antagonist in combination with either: (a) a sodium channel antagonist; (b) a nitric oxide synthase (NOS) inhibitor; (c) a glycine site antagonist; (d) a potassium channel opener; (e) an AMPA/kainate receptor antagonist; (f) a calcium channel antagonist; (g) a GABA-A receptor modulator (e.g., a GABA-A receptor agonist); or (h) an antiinflammatory agent. This invention also relates to methods of treating hypoxic or ischemic stroke comprising administering to a patient in need of such treatment an NMDA receptor antagonist in combination with a thrombolytic agent.
    Type: Grant
    Filed: September 6, 2001
    Date of Patent: November 23, 2004
    Assignee: Pfizer, Inc.
    Inventors: Bertrand L. Chenard, Frank S. Menniti, Mario D. Saltarelli
  • 3-heterocyclylpropanohydroxamic acid PCP inhibitors
    Patent number: 6821972
    Abstract: Compounds of formula (I): and their salts, solvates, hydrates and prodrugs are useful PCP inhibitors, processes for making the same, compositions comprising the same, and methods of treating a PCP-mediated condition or disease using the same.
    Type: Grant
    Filed: March 29, 2002
    Date of Patent: November 23, 2004
    Assignee: Pfizer Inc.
    Inventors: Simon Bailey, Paul Vincent Fish, Kim James, Gavin Alistar Whitlock
  • Antidiabetic agents
    Patent number: 6821977
    Abstract: A compound of the formula whereon R1 is: R5 is: and n, m, Z, R8, R9, R10 and R11 are as defined herein, useful in the treatment of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis, and tissue ischemia, particularly myocardial ischemia.
    Type: Grant
    Filed: February 19, 2003
    Date of Patent: November 23, 2004
    Assignee: Pfizer, Inc.
    Inventor: Ronald B. Gammill
  • Method and device for NIR reflection spectroscopy
    Publication number: 20040227086
    Abstract: A method and a device for the analysis of products in the form of a capsule, and of empty capsules, by means of NIR reflection spectroscopy are provided wherein the capsule is rotated around at least one axis during the recording of the reflection spectrum. Means for rotating the capsule are also provided.
    Type: Application
    Filed: March 4, 2004
    Publication date: November 18, 2004
    Applicant: Pfizer Inc
    Inventors: Holger Gerhard Haug, Alexander Pysik
  • Certain alkylene diamine-substituted heterocycles
    Publication number: 20040229870
    Abstract: The present invention also provides a general method to whereby mono-, bi-, or tricyclic heterocycles may be modified to obtain potent antagonists at the NPY1 receptor.
    Type: Application
    Filed: November 10, 2003
    Publication date: November 18, 2004
    Applicants: NEUROGEN CORPORATION, PFIZER INC.
    Inventors: Raymond F. Horvath, Jennifer N. Tran, Stephane De Lombaert, Kevin J. Hodgetts, Philip A. Carpino, David A. Griffith
  • Purine derivatives
    Publication number: 20040229838
    Abstract: The present invention relates to compounds of the formula 1
    Type: Application
    Filed: June 15, 2004
    Publication date: November 18, 2004
    Applicant: Pfizer Inc
    Inventors: Simon John Mantell, Sandra Marina Monaghan, Peter Thomas Stephenson
  • 5HT7 Antagonists and inverse agonists
    Publication number: 20040229874
    Abstract: The present invention relates to compounds of formula I, 1
    Type: Application
    Filed: January 27, 2004
    Publication date: November 18, 2004
    Applicant: Pfizer Inc.
    Inventors: Gene Michael Bright, Karen J. Coffman
  • Treatment of hypertension
    Publication number: 20040229933
    Abstract: The present invention relates to the use of a modulator of the Kiss-1 receptor for the treatment of blood pressure disorders, in particular to the use of a Kiss-1 receptor antagonist for the treatment of hypertension. The invention also provides methods of screening for compounds useful in the treatment of hypertension.
    Type: Application
    Filed: July 16, 2004
    Publication date: November 18, 2004
    Applicant: Pfizer Inc
    Inventor: Sidath Dhammika Katugampola
  • Anti-diabetic agents
    Publication number: 20040229916
    Abstract: The present invention provides compounds of formula (I) 1
    Type: Application
    Filed: April 15, 2004
    Publication date: November 18, 2004
    Applicant: Pfizer Inc
    Inventors: Donald L. Bussolotti, Ronald B. Gammill
  • New pharmaceutical combinations for NOS inhibitors
    Publication number: 20040229911
    Abstract: The present invention relates to new pharmaceutical uses for compounds that exhibit activity as nitric oxide synthase (NOS) inhibitors. Specifically, it relates to the use of NOS inhibitors, particularly selective neuronal NOS (nNOS) inhibitors, alone or in combination with another active agent, in particular, either an SSRI or an NK-1 receptor antagonist, for the treatment of disorders or conditions the treatment which can be effected or facilitated by altering circadian rhythms. Examples of such disorders and conditions are blindness, obesity, seasonal affective disorder, bipolar disorder; jet lag, circadian sleep rhythms disorder, sleep deprivation, parasomnias, REM sleep disorders, hypersomnia, sleep-wake cycle disorders, narcolepsy and sleep disorders associated with shift work or irregular work schedules; nocturnal enuresis, and restless-legs syndrome.
    Type: Application
    Filed: June 14, 2004
    Publication date: November 18, 2004
    Applicant: Pfizer Inc
    Inventors: Mario David Saltarelli, John Adams Lowe
  • Compounds useful for the treatment of diseases
    Publication number: 20040229904
    Abstract: The invention relates to compounds of formula (1) 1
    Type: Application
    Filed: May 6, 2004
    Publication date: November 18, 2004
    Applicant: Pfizer Inc
    Inventors: Mark Edward Bunnage, Paul Alan Glossop, Charlotte Alice Louise Lane, Russell Andrew Lewthwaite
  • Human monoclonal antibodies to CTLA-4
    Publication number: 20040228858
    Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
    Type: Application
    Filed: July 1, 2003
    Publication date: November 18, 2004
    Applicants: Pfizer Inc., Abgenix, Inc.
    Inventors: Douglas Charles Hanson, Mark Joseph Neveu, Eileen Elliott Mueller, Jeffrey Herbert Hanke, Steven Christopher Gilman, C. Geoffrey Davis, Jose Ramon Corvalan
  • Process to produce enantiomerically enriched alcohols and amines
    Publication number: 20040230081
    Abstract: This invention describes a convenient method for the preparation and use of a ruthenium catalyst for a chiral reduction of ketones and imines.
    Type: Application
    Filed: March 19, 2004
    Publication date: November 18, 2004
    Applicant: Pfizer, Inc.
    Inventors: Steven P. Tanis, Bruce Evans
  • Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
    Publication number: 20040224963
    Abstract: Pharmaceutical compositions are disclosed for the treatment of nicotine dependence or addiction, tobacco dependence or addiction, reduction of nicotine withdrawal symptoms or aiding in the cessation or lessening of tobacco use or substance abuse or other behavioral dependencies. The pharmaceutical compositions are comprised of a therapeutically effective combination of a nicotinic receptor partial agonist and a CB-1 receptor antagonist and a pharmaceutically acceptable carrier. The method of using these compounds is also disclosed.
    Type: Application
    Filed: March 4, 2004
    Publication date: November 11, 2004
    Applicant: Pfizer Inc
    Inventors: Jotham W. Coe, Philip A. Iredale, Steven B. Sands
  • Use of protein kinase C inhibitor for suppressing sustained slow postsynaptic excitation (SSPE)
    Publication number: 20040224937
    Abstract: A novel use of an inhibitor of protein kinase C (PKC) for suppressing the sustained slow postsynaptic excitation (SSPE) caused by prolonged stimulation of synaptic inputs to intrinsic primary afferent neurons (IPANs), is provided. Since the generation of SSPE requires a phosphorylation step mediated by protein kinase C, PKC inhibitors, such as staurosporine, RO31-8220 or calphostin C is useful for a method for the treatment of a patient having a need to suppress the sustained slow postsynaptic excitation (SSPE) caused by prolonged stimulation of synaptic inputs to intrinsic primary afferent neurons (IPANs), such as intestinal hypersensitivity, irritable bowel syndrome (IBS), non-ulcer dyspepsia, or other conditions that may derive from long-term changes in the behavior of enteric neurons.
    Type: Application
    Filed: March 26, 2004
    Publication date: November 11, 2004
    Applicant: Pfizer Inc
    Inventors: John B. Furness, Martin J. Stebbing
  • Nicotinamide derivatives useful as PDE4 inhibitors
    Publication number: 20040224975
    Abstract: The invention relates to nicotinamide derivatives and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The nicotinamide derivatives according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic, respiratory diseases, disorders and conditions, as well as wounds.
    Type: Application
    Filed: June 9, 2004
    Publication date: November 11, 2004
    Applicant: Pfizer Inc.
    Inventors: Simon Balley, Elisabeth C. L. Gautier, Alan J. Henderson, Thomas V. Magee, Anthony Marfat, John P. Mathias, Dale G. McLeod, Sandra M. Monaghan, Blanda L. C. Stammen